skip to navigation skip to content

Manufacturing Chemist: Limits of drug repurposing


New research co-authored at Cambridge Judge Business School looks at drug repurposing and found that it’s not easy to find entirely new uses for existing molecules. The study is based on US Food and Drug Administration approvals and the full clinical development history of more than 800 new molecular entities over a 32-year period. “Attempting to repurpose some drugs can be a good approach given the rising costs of new drug development, but the data shows a low overall success rate for repurposing – particularly in producing successes in a new disease setting,” said co-author Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge.

Read the full article []